Clinical Report: Women and Liver Fibrosis Risk: New Insights

Overview

A recent study highlights sex-specific differences in the association between cardiometabolic risk factors and liver fibrosis, revealing that women exhibit higher odds of significant fibrosis linked to certain metabolic conditions, such as glucose intolerance and high waist circumference, compared to men. The findings underscore the need for tailored risk assessment strategies in clinical practice.

Background

Understanding the relationship between cardiometabolic risk factors and liver fibrosis is crucial, as liver fibrosis can lead to severe complications, including liver cancer. This study provides insights into how these associations differ by sex, which may influence screening and management strategies for at-risk populations. The findings are particularly relevant given the rising prevalence of metabolic disorders and nonalcoholic fatty liver disease (NAFLD).

Data Highlights

Key Findings

• Women have a lower overall prevalence of significant liver fibrosis (6.9%) compared to men (10.7%).
• High waist circumference is more strongly associated with fibrosis in women, with odds over 13 times higher in those affected.
• Glucose intolerance shows a higher odds ratio for fibrosis in women (2.94) compared to men (1.51).
• The presence of multiple cardiometabolic risk factors is more strongly linked to fibrosis in women than in men.
• Women exhibited a higher prevalence of elevated waist circumference (69.0%) compared to men (48.6%).
• The study's cross-sectional design limits the ability to determine causality.

Clinical Implications

Healthcare professionals should consider sex-specific differences when assessing liver fibrosis risk in patients with cardiometabolic conditions. Enhanced screening strategies, such as using transient elastography and monitoring waist circumference and glucose levels, may be warranted for women, particularly those with high waist circumference and glucose intolerance, to improve early detection and management of liver fibrosis.

Conclusion

The study emphasizes the importance of recognizing sex differences in the relationship between cardiometabolic risk factors and liver fibrosis, which may inform future clinical guidelines and risk assessment strategies.

References

1. Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis | Gastroenterology and Hepatology | JAMA Network, 2023 -- Women and Liver Fibrosis Risk: New Insights
2. The New Gastroenterologist — MASLD fibrosis significantly drives HCC risk, study finds, 2026
3. The New Gastroenterologist — Addressing NAFLD: Strategies to Alleviate the Effects of Nonalcoholic Fatty Liver Disease, 2025
4. The Journal of Clinical Endocrinology & Metabolism — Additional Predictive Value of Blood-Based Liver Fibrosis Indicators in Assessing Cardiovascular Risk, 2025
5. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC, 2024
6. The New Gastroenterologist — Gender Disparities in Alcohol-Related Hepatitis: Increased Risk for Women
7. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC
8. Drug Trials Snapshots: REZDIFFRA | FDA
9. Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis | Gastroenterology and Hepatology | JAMA Network Open | JAMA Network